|
|
|
| Diagnostic Value of Circulating Tumor Cells Combined with Tumor Markers in the Detection of Advanced Non-small Cell Lung Cancer |
| FEI Xiao-dong |
| The people's Hospital of Xuyang,Jiangshu 213300 |
|
|
|
Abstract 【Objective】To explore the diagnostic value of circulating tumor cells (CTC) combined with serum tumor markers in patients with advanced non-small cell lung cancer (NSCLC). 【Methods】A total of 84 patients with pathological diagnosis of ⅢB ~Ⅳ NSCLC were selected as the observation subject (NSCLC group ). In addition, 60 patients with benign lung lesions served as the control group. MACS negative enrichment joint immunocytochemistry was used to detect peripheral blood CTC. Meanwhile, ECL method usage compared the levels of CTC, serum CEA, CA125 and CA199 in peripheral blood between the two groups. 【Results】Generally, the detection levels were significantly higher in the observation group than in the control (P<0.05) in terms of CTC, CEA, CA199 and CA125 positive rates. Judging by CTC detection, the differential diagnosis of NSCLC patients had a sensitivity of 64.29% and a specificity of 96.67%. CEA differential diagnosis of NSCLC was 47.62% in sensitivity and 86.67% in specificity. Differential diagnosis of NSCLC by CA199 resulted in sensitivity of 36.90% and specificity of 76.67%. In the combination of CTC + CEA + CA125 + CA199, the differential diagnosis of NSCLC patients reached sensitivity of 88.10% and specificity of 96.67 %.【Conclusion】CTC combined with serum tumor markers for differential diagnosis of patients with advanced NSCLC can be significantly improved.
|
|
Received: 04 July 2016
|
|
|
|
|
|
[1] Tseng CC, Wang CC, Hsiao CC,et al. Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention[J].Tumour Biol,2016,34(05):90-93.
[2] 孙常铭,王丽萍,刘敏,等. 血清中期因子联合癌胚抗原检测对非小细胞肺癌的诊断价值[J].广东医学,2015,26(05):768-769.
[3] Sacher A G, Le LW, Lara-Guerra H, et al. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer[J].Oncotarget,2016,42(05):102-105.
[4] Sawabata N, Funaki S, Hyakutake T, et al. Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood[J].Surg Today,2016,33(09):34-37.
[5] Mascalchi M, Falchini M, Maddau C, et al. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC[J].J Cancer Res Clin Oncol,2016,142(1):195-200.
[6] 陈礼文,盛守琴,周强,等. CEA与CYFRA21-1在非小细胞肺癌血清和胸腔积液差异表达及其相关性分析[J].实用医学杂志,2014,30(08):1221-1224.
[7] 尚立群,赵皆,王伟,等. 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响[J].中国肺癌杂志,2014,34(10):722-729.
[8] 李晶,姜北,万鹏,等. 晚期非小细胞肺癌患者循环肿瘤细胞检测的临床意义[J].中国全科医学,2013,16(27):3202-3204.
|
|
|
|
2017, Vol. 34 
